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Abstract 
 
Minimizing time delays in manufacturing vaccines appropriate to rapidly mutating viruses 
is the key step for improving vaccine effectiveness.  The vaccine for the H3N2 flu type 
has failed for the last two years (~ 15% effective). Here we summarize the state of the 
predictive art and report the most current results for H3N2 flu vaccine design.  Using a 
2006 model of dimensional reduction of viral mutational complexity, we show that this 
model can reduce vaccine time delays by a year or more in some cases. 
 
Viruses are hypermutated proteins, with nearly one mutation per replication [1].     This rapid mutation 
allows selection for viruses that succeed in evading antibody-mediated immunity.  In a computational 
view the most successful strains tend to form clusters that are visible in a reduced, two-dimensional 
sequence space.  This cluster of strains remains until sufficiently recognized by antibodies in the human 
population [2], at which point selection leads to a new antibody-evading strain, which initiates a new 
cluster.   This process is a dramatic example of punctuated evolution [3-5], and it is modelled with 
cluster-specific immunity [6].  There are several types of flu viruses, and the current vaccine cocktail 
treats the most common three.  The oldest type A/H1N1 was responsible for both the deadly 1918 and 
the comparatively harmless 2009 “swine flu” pandemics.  The A/H1N1 type strains have stabilized, are 
milder, and are more effectively vaccinated against.  More morbidity and mortality are now associated 
with rapidly mutating A/H3N2 strains, which are discussed here.  
 
There are two major problems facing the vaccination community.  The first is the lengthy temporal delay 
between the arrival of new evasive viral strains, their reported sequencing, and determination of 
suitability of new strains as vaccine targets.  The second is the effect of mutations in the currently 
circulating strains on the effectiveness of vaccines based on older strains, often including another 
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lengthy delay due to collection of ferret animal model data.  Traditionally these two problems have most 
often been treated separately, while a unified treatment could result in a dramatic acceleration of 
vaccine design. 
 
Early strain clustering efforts utilized both indirect measurements of viral activity, for instance, by 
measuring ferret responses, as well as molecular evolution at the amino acid sequential level [7,8].  In 
the latter method, sequences are unambiguous, and the historical sequence data base has grown to be 
much larger and more timely than the still sparse and lagging-by-years ferret viral activity database 
[9,10].  As a result, since 2006 both improved clustering and better dominant strain predictive results 
have been obtained bioinformatically for H3N2 using sequences alone.  Until 2010, annual H3N2 
differences were small, and the two methods were almost equally successful (8 out of 10 years for the 
mixed ferret-sequence method, improved to  9 out of 10 for the pure sequence method) [11,12].  
 
Sequential substitutional displacements can be measured in different ways.  One measure of distance 
between any two sequences is the number of mutations [9].  The most substitutionally active part of flu 
viruses is the ~ 100 amino acid head region 115-215 of the hemagglutinin protein, HA1, which contains 
329 amino acids.  A more refined measure of difference between strains begins by identifying the five 
HA1 epitopic subsets (A-E), containing the most frequently mutated amino acids in a given year, with the 
A and B epitope patches concentrated at the top of the head region, near the sialic acid receptor [7,8].   
 
The best correlation with vaccine effectiveness to date defines distances between sequences in terms of 
the numbers of mutations at epitopic sites, normalized by the size of the epitope, and identifies the 
epitope that is dominating the difference between the current circulating strain and the lagging vaccine 
strain [8].  The fractional number of all mutations of this dominant epitope, pepitope, gives the best 
correlation with vaccine efficacy [7,9], with R
2
 ~ 0.8 over the period 1971-2015, which is much better 
than one obtains from ferret data, or mixed ferret- sequence data, R
2
 ~ 0.5 [8].   
 
An accurate and rapid way to quantify strain drift [9,10], and at the same time recognize formation of 
clusters of new strains, is to compress dimensionally the interstrain distances in the full amino acid 
space (for A/H3N2, 329 dimensions) to the two eigenvectors best capable of minimizing the interstrain 
distances over a time frame of about three years [7,11].  Dimensional compression of sequences is 
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unbiased, and is compatible with epitopic analysis [11,12].  Here the compression from 329 dimensions 
to only two dimensions can be regarded as an extreme case, which can introduce both common and 
distinctive features as new data are added.  This point is discussed in Figs. 1 and 2, showing strain cluster 
evolution over 3 months in 2014-2015.   
 
The most obvious feature of Fig. 1 (2012- Fall 2014) is the large separation between Texas 2012  and the 
central 2013-2014 cluster, with pepitope = 0.19 (derived from the B epitope), which explains why the 
2013 and 2014 vaccines based on Texas 2012  have failed [13].  The strain selected by the World Health 
Organization as the target for the 2015 vaccine is Switzerland 2013.  This was a novel cluster in 2014, but 
there is another novel cluster in 2014-2015, centered near Nebraska 2014.  The pepitope separating these 
two different 2015 candidate clusters (derived from the A epitope) is 0.16, only slightly smaller than 
vaccine target and dominant strain pepitope = 0.19 in failed vaccine years2013-2014.   
 
Next we look carefully at the Nebraska 2014 cluster, and compare with Switzerland 2013.  Which better 
represents the dominant circulating strain for 2015?  In Fig. 2 we show what happens when the late 
2014 strains reported in early 2015 are added to Fig. 1.  The axes are rotated, and Switz moves closer to 
centered earlier strains, while >90% of the new strains are added to the well-separated Nebraska 2014 
cluster.  This is still far from the vaccine target strain Switz 2013 cluster, with a separation value of pepitope 
= 0.16 large enough to predict vaccine failure again in 2015-2016 [13]. 
 
It is tempting to suppose that perhaps better predictability could be achieved by including deleterious 
(mostly C-E epitopes) mutations outside the A-B receptor region phylogenetically [14].  In this way, and 
using observed sequence data to estimate clade “fitness,” some encouraging H3N2 results (inset to their 
Fig. 3) were obtained.  These results stopped short of reaching a correlation with vaccine effectiveness 
similar to that already reported earlier [8] for A/H3N2 using all epitopes.  There are several toy models 
of network “fitness” [15], but they all involve only short-range connectivity, and no long-range forces.  
Long-range forces can be modelled using hydropathic profiles, but as we shall soon see, they are not 
needed here for predicting H3N2 vaccine targets [16-19].  Note the two striking nearly linear regions 
associated with different years in Fig. 2.  These were already present in Fig. 1, but the lines have 
straightened and narrowed in Fig. 2.  This novel feature deserves more study.  It is unlikely to be 
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accidental: it could represent the effect of long-range interactions on the dominant epitope, which 
changed from B to A from 2012-2013 to 2014 [13].  
 
Why is the dominant epitope model so effective?  A toy model describes the A-B epitope dominance 
switching as vector “canalization” [20], which could be generalized to identify a single antigenic axis for 
each dominant epitope.     Markov analysis explored this question at length for the historical H3N2 
switching between A and B dominant epitopes (1971-2004), and two results emerged [12]:  (1) The A 
and B epitopes both combine hydrophobic and charged amino acid features, but with inverted 
conserved hydrophobic structures (epitopic corners A, and center B); and  (2) There was a positive 
selective pressure for increasing charged amino acids in the immunodominant epitopes, which decrease 
absolute values of binding energies of epitopes to antibodies, by increasing the epitope’s affinity for 
water.  Further examination of A and B epitopes, 2004-2014 [13], reveals qualitative differences in A-B 
switching before and after 2000, which will be discussed elsewhere. 
 
In conclusion, rapid and reliable identification of emergent strain clusters is the key to developing an 
effective flu vaccine.  Traditional measurements of viral antigenicity or phylogenetic theories, or their 
combination, omit highly informative structural data used to define epitopes [22-24], and have had only 
limited success (R
2
 ~ 0.5).  Dimensional reduction in three- year time-frame sliding sequence space, 
supported by identifying dominant epitopes [8,11-13], has proved to be more effective for H3N2 (R
2
 ~ 
0.8).  The stakes here are high: a one-year delay in finding new H3N2 clusters has an equivalent 
economic value > $10 billion (a conservative estimate, considering that H3N2 morbidity is several times 
higher than for H1N1 [25]).   The failure of the H3N2 2014-2015 vaccine in America was responsible for 6 
million additional flu cases lasting several weeks, disrupted many hospitals, and undermined public 
confidence in vaccinations. 
 
Because of record late Nov. - Dec. temperature highs (~ 10°C above normal) in most of America, 2015-
2016 American flu infections, reported online weekly at CDC FLUVIEW, are ambiguous at this writing.  
We predict that when winter temperatures return to normal, 2015 flu epidemic severity will be less than 
2014, with pepitope = 0.19, but more than 2013, with pepitope = 0.14, as predicted by the A/Switzerland-
Nebraska difference with pepitope = 0.16 [13]. 
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Figure Captions 
 
Fig. 1.  Dimensional reduction of all HA1 sequences deposited in Genbank in the time frame 
from 2012 through 12/2014 [13].  As the color coding shows, the Nebraska 2014 cluster began 
to appear as a few strains by Dec 2013, and contained > 10 strains by Mar 2014.  The Cal 2014  
cluster also contains the WHO vaccine target strain Switz 2013. 
 
Fig. 2.  Most of the 877 late 2014 strains reported in early 2015 are concentrated in the 
Nebraska 2014 cluster, which is far separated from the Switz 2013 cluster.  These figures are 
best viewed online at high magnification.  In addition to the two clusters there are also two 
linear “canals” associated with 2012-early 2013, and late 2014.  The largest difference between 
Figs. 1 and 2 is merely rotation of the coordinates.  The origins are the center of masses, which 
are little changed.  For clarity the graphical resolution of 4754 points (877 added to Fig. 1) is 
limited.   
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Fig. 2
  
